133 related articles for article (PubMed ID: 26007262)
21. Clinical significance of the tumour markers CA 125 II and CA 72-4 in ovarian carcinoma.
Hasholzner U; Baumgartner L; Stieber P; Meier W; Reiter W; Pahl H; Fateh-Moghadam A
Int J Cancer; 1996 Aug; 69(4):329-34. PubMed ID: 8797878
[TBL] [Abstract][Full Text] [Related]
22. Evaluation in the predictive value of serum human epididymal protein 4 (HE4), cancer antigen 125 (CA 125) and a combination of both in detecting ovarian malignancy.
Teh BH; Yong SL; Sim WW; Lau KB; Suharjono HN
Horm Mol Biol Clin Investig; 2018 Jul; 35(1):. PubMed ID: 30063463
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of Serum Nidogen-2 as a Screening and Diagnostic Tool for Ovarian Cancer.
Torky HA; Sherif A; Abo-Louz A; Ali M; Ahmed A; Ali A
Gynecol Obstet Invest; 2018; 83(5):461-465. PubMed ID: 29131023
[TBL] [Abstract][Full Text] [Related]
24. Peritoneal fluid lactate dehydrogenase in ovarian cancer.
Schneider D; Halperin R; Langer R; Bukovsky I; Herman A
Gynecol Oncol; 1997 Sep; 66(3):399-404. PubMed ID: 9299252
[TBL] [Abstract][Full Text] [Related]
25. Pre-operative evaluation of ovarian mass: risk of malignancy index.
Asif N; Sattar A; Dawood MM; Rafi T; Aamir M; Anwar M
J Coll Physicians Surg Pak; 2004 Mar; 14(3):128-31. PubMed ID: 15228841
[TBL] [Abstract][Full Text] [Related]
26. Comparison of risk of malignancy index (RMI), CA125, CA 19-9, ultrasound score, and menopausal status in borderline ovarian tumor.
Alanbay I; Akturk E; Coksuer H; Ercan M; Karaşahin E; Dede M; Yenen MC; Ozan H; Baser I
Gynecol Endocrinol; 2012 Jun; 28(6):478-82. PubMed ID: 22122561
[TBL] [Abstract][Full Text] [Related]
27. Accuracy of tissue polypeptide specific antigen (TPS) in the diagnosis of ovarian malignancy.
Padungsutt P; Thirapagawong C; Senapad S; Suphanit I
Anticancer Res; 2000; 20(2B):1291-5. PubMed ID: 10810437
[TBL] [Abstract][Full Text] [Related]
28. [Application values of four risk of malignancy indices in the preoperative evaluation of patients with adnexal masses].
Lou HY; Meng H; Zhu QL; Zhang Q; Jiang YX
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Jun; 32(3):297-302. PubMed ID: 20602883
[TBL] [Abstract][Full Text] [Related]
29. Radioimmunoscintigraphy with Tc-99m-labelled SM3 in differentiating malignant from benign adnexal masses.
Ali N; Jan H; Van Trappen P; Nasreen F; Canizales A; Carroll MJ; Granowska M; Jacobs I; Britton KE
BJOG; 2003 May; 110(5):508-14. PubMed ID: 12742337
[TBL] [Abstract][Full Text] [Related]
30. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A
Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929
[TBL] [Abstract][Full Text] [Related]
31. Differential diagnosis of ovarian cancer with tumour markers CA 125, CA 15-3 and TAG 72.3.
Jacobs IJ; Rivera H; Oram DH; Bast RC
Br J Obstet Gynaecol; 1993 Dec; 100(12):1120-4. PubMed ID: 8297846
[TBL] [Abstract][Full Text] [Related]
32. Accuracy of intra-operative frozen section analysis of ovarian tumours.
Gorisek B; Stare MR; Krajnc I
J Int Med Res; 2009; 37(4):1173-8. PubMed ID: 19761701
[TBL] [Abstract][Full Text] [Related]
33. [Usefulness of clinical evaluation for the level of CA-125 antigen and ultrasonographic color Doppler examination in diagnosis of ovarian tumor].
Czekierdowski A; Zrubek H; Sikorski M; Wiktor H; Józefczak M; Stachowicz N
Ginekol Pol; 1996 Nov; 67(11):552-6. PubMed ID: 9289441
[TBL] [Abstract][Full Text] [Related]
34. Urinary gonadotropin peptide (UGP) and serum CA 125 in gynaecologic practice, a clinical prospective study.
Schutter EM; Mijatovic V; Kok A; Van Kamp GJ; Verstraeten R; Verheijen RH
Anticancer Res; 1999; 19(6C):5551-7. PubMed ID: 10697615
[TBL] [Abstract][Full Text] [Related]
35. Comparison of Serum CA72-4 and CEA Levels in Patient with Endoscopically Suspected Gastric Carcinoma.
Rehena Z; Ghosh CK; Afroz F; Alam MB; Ferdousi S; Mahmuduzzaman M; Sultana T; Ahmed AN
Mymensingh Med J; 2015 Jul; 24(3):542-9. PubMed ID: 26329953
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma.
García-Velloso MJ; Jurado M; Ceamanos C; Aramendía JM; Garrastachu MP; López-García G; Richter JA
Eur J Nucl Med Mol Imaging; 2007 Sep; 34(9):1396-405. PubMed ID: 17318549
[TBL] [Abstract][Full Text] [Related]
37. Increased serum 72 KDa metalloproteinase in serous ovarian tumors: comparison with CA 125.
Garzetti GG; Ciavattini A; Lucarini G; Goteri G; Romanini C; Biagini G
Anticancer Res; 1996; 16(4A):2123-7. PubMed ID: 8712754
[TBL] [Abstract][Full Text] [Related]
38. Preoperative assessment of ovarian tumors using a modified multivariate index assay.
Abdurrahman HA; Jawad AK; Alalalf SK
J Ovarian Res; 2018 May; 11(1):41. PubMed ID: 29843758
[TBL] [Abstract][Full Text] [Related]
39. [Analysis of serum CA125, CEA, AFP, LDH levels and LDH isoenzymes in patients with ovarian tumors--correlation between tumor markers and histological types of ovarian tumors].
Konishi I; Fujii S; Okamura H; Sakahara H; Endo K; Torizuka K; Suzuki A; Mori T
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jun; 38(6):827-36. PubMed ID: 2426374
[TBL] [Abstract][Full Text] [Related]
40. CA 19-9 in evaluation of adnexal mass: retrospective cohort analysis and review of the literature.
Sagi-Dain L; Lavie O; Auslander R; Sagi S
Int J Biol Markers; 2015 Jul; 30(3):e333-40. PubMed ID: 25704505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
